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A genome scan for diabetic nephropathy in African Americans.
Background. There is substantial evidence for a genetic con-
tribution to diabetic nephropathy susceptibility in the African
American population, but little is known about location or iden-
tity of susceptibility genes.
Methods. DNA samples were collected from 206 type
2 diabetes (T2DM) and end-stage renal disease (ESRD)/
nephropathy-affected sib pairs from 166 African American
families (355 affected individuals). A genome scan was per-
formed and data analyzed using nonparametric linkage re-
gression (NPLR) analysis and ordered subsets analysis (OSA)
methods.
Results. In initial NPLR analyses no logarithm of odds (LOD)
scores >2.0 were observed. Four loci had LOD scores ≥1.0, with
LOD = 1.43 at 29 cM on chromosome 7p the highest. NPLR
analyses of multilocus interactions detected 6 loci (7p, 12p, 14q,
16p, 18q, and 21q) with LOD scores 1.15 to 1.63. NPLR analyses
evaluating phenotypic interactions revealed multiple locations
with evidence (P < 0.05) for interactions with age-at-onset of
ESRD (9 loci), duration of diabetes before onset of ESRD (19
loci), and age-at-onset of diabetes (14 loci). Several loci iden-
tified by NPLR analyses were also identified using OSA. OSA
revealed evidence for a nephropathy locus at 135 cM on chro-
mosome 3 in an estimated 29% of the families (LOD = 4.55
in the optimal subset). Additional linkage evidence, LOD =
3.59, was observed on chromosome 7p (37% of the families,
longer duration of diabetes prior to diagnosis of ESRD), and
18q (max. LOD = 3.72; 64% of the families, early diabetes di-
agnosis). The 7p linkage has been observed in a recent genome
scan of African American type 2 diabetes.
Conclusion. This first genome scan of diabetic nephropathy
in African Americans reveals evidence for susceptibility loci on
chromosomes 3q, 7p, and 18q. The 7p locus may represent a
type 2 diabetes susceptibility locus.
African Americans have a 2.6- to 5.6-fold increased
risk of developing end-stage renal disease (ESRD) com-
pared to other racial/ethnic groups in the United States
[1], and make up almost half of the individuals on renal
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replacement therapy. Diabetes-associated nephropathy
is the most common source of ESRD and accounts for
approximately 40% of cases in the United States. There
is now extensive evidence, based upon a variety of ap-
proaches [2], that ESRD in the general population, and
African Americans specifically, has a genetic component.
African Americans have a significantly stronger familial
aggregation of ESRD: a close relative with ESRD gives
an African American a 9-fold increased risk of devel-
oping ESRD [3] compared to an increased risk of only
2.7-fold in Caucasian Americans [4]. These results sug-
gest that there is a stronger familial component to ESRD
in the African American population, in addition to a dis-
proportionately higher incidence. The impact on public
health is substantial, but the origins of ESRD in the gen-
eral population are still poorly understood. Only some
diabetes-affected individuals will ultimately progress to
nephropathy and ESRD, suggesting that, in addition to
genetic susceptibility, environmental factors contribute
to nephropathy risk.
Many studies have been carried out that have eval-
uated the contribution of specific “candidate genes” to
ESRD and nephropathy susceptibility. A powerful alter-
native approach, the “genome scan,” is a comprehensive
genetic survey of the entire genome for chromosomal
regions that are coinherited (i.e., linked) with a specific
trait. The genome scan approach utilizes linkage analysis
of genetic markers evenly spaced over all of the chro-
mosomes in collections of families with multiply affected
individuals. The genome scan approach is more difficult,
time consuming, and expensive than candidate gene anal-
ysis, but has the advantage of being able to comprehen-
sively survey the genome and locate new, potentially as
yet undiscovered, genes. The limitation of the genome
scan approach is that while it usually has the power to
detect major genetic effects, it does not usually have the
power to detect loci with small effects. Importantly, the
genome scan approach is not limited by prior knowledge
of, in this case, renal disease biology. We have performed
the first such genome scan of diabetic nephropathy in
African Americans in an effort to better understand the
genetic contributors to this disorder.
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METHODS
Subjects
DNA samples were collected from self-described
African American families with multiple type 2 diabetes
mellitus (T2DM) and ESRD or nephropathy-affected
members. Briefly, families were originally identified
through a proband with ESRD associated with T2DM.
T2DM was diagnosed in probands developing diabetes
and treated with diet and exercise or oral hypoglycemic
agents during at least part of their disease history. Med-
ical records were reviewed to verify the etiology of the
nephropathy. Renal failure was attributed to diabetes in
the presence of the following criteria: serum creatinine
≥2.0 mg/dL with either diabetes duration for >10 years,
or proliferative diabetic retinopathy in the absence of
other known causes of renal failure. When proteinuria
data were available, all subjects had proteinuria ≥500 mg/
24 hours, a urine protein:creatinine ratio ≥0.5 mg/g
or ≥100 mg/dL proteinuria on urine dipstick. Diabetic
nephropathy (DN) affected siblings, and, when possible,
other available family members were also recruited. Re-
cruitment strategies and selection criteria have been de-
scribed in detail previously [5–10]. The family set for the
genome-wide scan comprised 166 African American fam-
ilies, with 206 (176 full-sibs and 30 half-sibs) DN-affected
sibling pairs (ASP) totaling 355 affected individuals. One
hundred forty-nine of the families contained 2 affected
siblings, 15 families had 3 affected siblings, and 2 fam-
ilies had 4 affected siblings. In general, the family data
consisted primarily of individuals from a single genera-
tion, with both parents available in none of the families,
and one parent for 10 families. Of the affected individ-
uals, 278 had T2DM with ESRD and 77 had diabetes
with chronic renal failure (CRF). Sixty-eight individuals
in the families had T2DM without a diagnosis of ESRD
or CRF, 46 of which were unaffected and 22 had unknown
renal status. For the purposes of this manuscript ESRD-
and CRF-affected individuals have been treated the same
and are described collectively as DN-affected individuals,
with the exception of analyses that incorporate age at di-
agnosis of ESRD and duration of diabetes to ESRD. In
these cases, only ESRD cases (and not CRF cases) were
incorporated into the models since clear definition of age
at onset of CRF was not possible.
Genotyping
DNA extraction was performed using the Pure-
Gene system (Gentra Systems, Minneapolis, MN, USA).
Through the International Type 2 Diabetes Linkage
Analysis Consortium, funded by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK),
a genome-wide scan was completed by the Center for In-
herited Disease Research (CIDR). The marker set used
was based on Marshfield Panel 8, with approximately
10% of the markers changed from the previous Marsh-
field panel. It consisted of largely tetra- and tri-nucleotide
repeats, and included 392 primer pairs at an average
spacing of 8.9 cM, and no intermarker gaps greater than
18 cM.
Each pedigree was examined for consistency of famil-
ial relationships using Pedigree RElationship Statistical
Test (PREST) [11]. When the self-reported familial re-
lationships were inconsistent with that determined from
the observed genotypic data for that pedigree, then (1)
the pedigree was modified when the identity by descent
(IBD) statistics suggested a very clear alternative, or (2)
a minimal set of genotypic data was converted to missing.
A total of 28 pedigrees (17%) exhibited probable incor-
rect familial relationships and were modified as above,
with 96% (27 of 28 families) of these changes being from
a full-sibling to half-sibling relationship. Each genetic
marker was also examined for Mendelian inconsisten-
cies using PedCheck [12], and sporadic problem geno-
types converted to missing. Allele frequency estimates
were derived from the genome scan genotyping data from
the families through computing the maximum likelihood
methods implemented in the software Recode (D. Weeks,
personal communication). Map distances were based on
the Marshfield genetic map [13].
Linkage analyses
Multipoint linkage analyses were carried out using
nonparametric linkage (NPL) regression analyses using
the NPLpairs statistics outputted from a modified version
of Genehunter [14–17]. The NPL regression approach
is a conditional logistic regression analysis in which the
family-specific NPL statistic (e.g., NPLpairs) at one or
more loci is the predictor variable. Consider a sample
of m independent pedigrees and a chromosomal region
with one or more markers and a locus of interest. Let s i
be the pedigree-specific contribution to the NPL statis-
tic at the locus of interest. The likelihood function for a
conditional logistic regression with s i as a predictor is
Lik(b ; yi , s) ∝
m∏
i=1
[
exp{yi si b}
1 + exp{si b}
]
.
Here, yi = 1 for all i, and b is the conditional logistic
regression parameter. It can be shown that the score
test from this likelihood is asymptotically equivalent to
Whittemore and Halpern’s class of tests [18]. Although
unaffected individuals can be used to help estimate the
possible inheritance vectors for that pedigree, an NPL re-
gression analysis is an “affected’s only” analysis. The pri-
mary advantage of the NPL regression approach is that
it allows us to evaluate simultaneously, either by joint or
conditional hypothesis tests, the effects of multiple loci
(i.e., heterogeneity) and test for interactions among sets
of loci (e.g., epistasis). To test for an interaction between
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two loci, the two locations and their statistical interaction
were included into the model and the 1 degree of free-
dom test of the interaction coefficient was computed. We
also tested for interactions between the degree of sharing
(IBD) at a location and (1) the mean age of diagnosis of
ESRD, (2) mean duration of diabetes before diagnosis of
ESRD, and (3) the mean age of diagnosis of diabetes.
Ordered subsets analysis
If a subset of pedigrees that are phenotypically more
homogeneous can be identified, it should be possible to
improve the power of linkage analysis. Ordered subset
analyses (OSA) [19] were computed to investigate the
influence of a pedigree’s mean age of diagnosis of ESRD,
mean age of diagnosis of diabetes, and mean duration of
diabetes before diagnosis of ESRD (similar to NPL re-
gression analysis above). OSA ranks each family by the
family-level value of a covariate of interest and identifies
the contiguous subset of families that maximize the evi-
dence for linkage. In the OSA with the mean age at ESRD
diagnosis, each pedigree was ranked from lowest to high-
est for age at ESRD diagnosis. The family with the lowest
mean age at ESRD diagnosis entered into the analysis,
and the corresponding LOD score was computed on the
target chromosome (e.g., chromosome 1) for that family.
Next, a second linkage analysis on the target chromo-
some 1 was computed, combining the two families with
the two lowest mean ages at ESRD diagnosis values. The
ith OSA analysis proceeds by computing a linkage analy-
sis on the target chromosome using the subset of families
with the ith lowest mean ages at ESRD diagnosis. This
process is repeated until all families have been added to
the linkage analysis. The subset of families that yield the
largest LOD score on the target chromosome is taken as
the LOD score of interest. The location that maximizes
the LOD score on a chromosome will vary as the subset
of families analyzed changes. The statistical significance
of the change in the LOD score was evaluated by a per-
mutation test under the null hypothesis that the ranking
of the covariate is independent of the family’s LOD score
on the target chromosome. Thus, the families were ran-
domly permuted with respect to the covariate ranking,
and an analysis proceeded as above for each permuta-
tion of these data. The resulting empirical distribution of
the change in the LOD scores yielded a chromosome-
specific P value. In this example, the family-level means
were ranked in ascending order; however, we repeated
the analysis ranking in descending order.
In several cases with the OSA we compared the de-
mographic characteristics of the optimal subset of fami-
lies showing evidence for linkage to the characteristics of
the remaining families. To compare phenotypes between
pedigrees that maximize evidence of linkage and the re-
maining pedigrees we computed a generalized estimating
Table 1. Characteristics of individuals in African American DN
families
Range
Trait Mean Median SD Low High
% Female 62.5% NA NA NA NA
Age at diabetes diagnosis 40.1 40.0 11.4 14 76
years
Age at ESRD diagnosis years 55.9 56.0 9.5 27 85
Diabetes to ESRD duration 17.6 17.0 9.4 0 49
years
Duration of ESRD at enrollment 3.5 2.0 3.7 0 24
years
Age at enrollment years 58.8 59.0 10.3 24 99
BMI kg/m2 31.2 30.1 7.3 15.2 64.8
HbA1c % 8.6 8.0 2.1 4.8 16
equation (GEE1) analysis, assuming exchangeable corre-
lation and a robust variance estimation [20].
RESULTS
Clinical and phenotypic data for African American DN
individuals
The clinical and phenotypic characteristics for the
genotyped DN affected individuals are summarized in
Table 1. The genotyped population was 62.5% female,
probably reflecting both the increased prevalence of
T2DM among African American women [21], survival,
and participation bias. The average age at diagnosis of
diabetes is relatively early at 40.1 years, with an aver-
age duration of diabetes of 17.6 years before the onset of
ESRD. The age at diabetes diagnosis and age at ESRD
onset are strongly correlated (r = 0.32, P < 0.0001).
There were 24 DN subjects with age at onset of dia-
betes less than 25 years of age. The average BMI at
enrollment into the study of this early diabetes onset
group was 31.7 (range 21.9 to 43.8), suggesting that
many of these individuals do have T2DM, but we can-
not exclude the possibility that some subjects have type
1 diabetes. Ten subjects were diagnosed with ESRD
and diabetes simultaneously. The great majority of the
ESRD affected subjects was enrolled within 5 years of
developing ESRD. Overall, the DN-affected individu-
als were obese at the time of their enrollment in the
study (median BMI >30). In this dataset there is no ev-
idence that duration of ESRD is significantly correlated
with BMI in this subject group (r = 0.006; P = 0.18).
The diabetes-affected individuals have relatively poor
glucose control (median HbA1c of 8.0% with the normal
range being 4.5% to 5.7%).
Single-locus linkage results
A multipoint linkage analysis was carried out and mul-
tipoint LOD score curves for each chromosome were gen-
erated. The maximum LOD score for each chromosome
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Table 2. NPL regression analysis of genome scan data: Single locus and multilocus interaction analysis
Single locus analysis Multilocus analysisPosition of Position Nearest
Chromosome of maximum LOD cM marker LOD LOD-1 interval P value LOD LOD-1 interval
1 73 D1S3721 0.91 38.0-87.5 0.041
2 248 D2S2968 0.15 231.0-257.5 0.401
3 6 D3S2387 0.34 pter-50.5 0.212
4 42.5 D4S391 0.61 16.5-72.0 0.094
5 130 D5S1505 0.39 65.0-148.5 0.178
6 165 D6S1035 0.89 115-qter 0.043
7 29 D7S3051 1.43 10.5-41.0 0.010 1.37 7.5-39
8 32.5 D8S1145 0.90 10.5-114.0 0.041
9 158.5 D9S1826 0.33 138.5-qter 0.214
10 149 D10S1656 0.89 79-qter 0.043
11 43 D11S1392 0.31 26.5-56.5 0.233
12 55 GATA91H0 1.06 24.5-75.5 0.027 1.38 37.5-76
13 83 D13S779 0.51 61.5-101.5 0.126
14 118.5 D14S1434 0.60 96.5-qter 0.098 1.23 105.5-qter
15 112 D15S966 0.09 106-qter 0.530
16 51.5 D16S769 1.00 26.0-79.5 0.032 1.63 37-70
17 125.5 D17S928 0.22 107.5-qter 0.310
18 99 D18S1364 1.07 69.5-qter 0.026 1.34 90.5-qter
19 45.5 D19S714 0.77 pter-81.5 0.060
20 44.5 D20S477 0.13 28.5-53.0 0.436
21 57.5 D21S1446 0.57 43.5-qter 0.105 1.15 20-qter
22 32 D22S685 0.97 pter-qter 0.035
NPL, nonparametric linkage.
and any secondary linkage peaks are presented in
Table 2. Only four regions of the genome yielded LOD
scores greater than 1. Chromosome 7 at 29 cM near
marker D7S3051 had the strongest evidence for linkage
with DN (LOD 1.43). Other regions with evidence for
linkage to DN were on chromosome 12 at 55 cM (near
GATA91H0, LOD 1.06), on chromosome 16 at 51.5 cM
(near D16S769, LOD 1.00), and on chromosome 18 at 99
cM (near D18S1364, LOD 1.07).
Multilocus and interaction linkage analysis results
With evidence that more than one genomic locus may
contribute to DN, the data were analyzed using a mul-
tilocus NPL regression model (Table 2). Six chromoso-
mal regions in 7p, 12p, 14q, 16p, 18q, and 21q remained
statistically significant (P < 0.05) after adjusting for the
evidence for linkage at the other five chromosomal re-
gions. Specifically, considering these loci within the same
model and computing the five 1 degree of freedom tests
of significance yielded increases in the LOD scores for
chromosomes 12p, 14q, 16p, 18q, and 21q, and a modest
decline in the LOD score for 7p relative to the corre-
sponding single-locus models for each locus. In each case
with the increased LOD scores, the LOD-1 interval also
narrows in the multilocus analysis.
NPL regression analysis: Interaction with
phenotypic traits
In all likelihood, multiple genetic loci contribute to
ESRD susceptibility. In some cases the presence of such
loci may be difficult to detect when assessed in the back-
ground of a large, heterogeneous mixture of families. This
possibility has been evaluated through the application of
the NPL regression analysis method to evaluate interac-
tions with phenotypic traits of age at ESRD diagnosis,
duration of T2DM prior to ESRD diagnosis, and age at
diagnosis of diabetes. The results of the NPL regression
locus-specific linkage are summarized in Table 3, where
regions showing statistically significant (P < 0.05) inter-
actions with the trait are listed, and the direction and
magnitude of the interaction is indicated by Pearson’s
correlation coefficient. These results suggest loci linked
to DN at several regions of the genome are detectable
when adjusting for age at ESRD diagnosis, duration of
diabetes prior to ESRD, or age at T2DM diagnosis. Anal-
ysis of interaction with age at ESRD diagnosis identifies 9
genomic locations that show significant interactions, with
loci on 1p at 89 cM and 3q at 140 cM having the strongest
evidence for linkage. Effects are observed in both direc-
tions (e.g., interactions with families with mean younger
age at diagnosis or older age at diagnosis). The negative
Pearson’s correlation coefficients indicate that interac-
tions were with lower mean ages of diagnosis, and the
linked families at the chromosome 1 locus were on av-
erage over 4.5 years younger, and on chromosome 3, 3.5
years younger at ESRD diagnosis than the unlinked fam-
ilies. A substantial number of loci, 19 in total, displayed
significant (P < 0.05) interactions with duration of T2DM
to onset of ESRD. The magnitude of these interactions
were, on average, stronger than for age at ESRD diag-
nosis, with P values ranging up to 0.00013 for interaction
on chromosome 16p at 23 cM in a group of families with
4 years longer duration of diabetes before ESRD onset. It
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Table 3. Results of NPL regression interaction analyses across the genome for age at diagnosis of ESRD, duration between diagnosis of diabetes
and ESRD, and age at diagnosis of type 2 diabetes in African American ESRD families
Mean ± SD (number of families)Position Nearest Interaction Pearson’s corrleation
Chromosome cM marker P value Linked families Unlinked families coefficient
Interaction with age at diagnosis of ESRD
1 89 D1S3728 0.007 53.6 ± 7.3 (52) 58.1 ± 7.9 (63) −0.27 (early onset)
2 247 D2S2968 0.042 55.0 ± 7.5 (54) 57.0 ± 8.3 (51) −0.19 (early onset)
3 140 D3S4523 0.016 54.6 ± 8.0 (65) 58.0 ± 7.5 (50) −0.22 (early onset)
4 99 D4S2361/D4S1647 0.045 55.2 ± 7.1 (49) 56.7 ± 8.5 (66) −0.13 (early onset)
5 0 D5S2488 0.022 54.9 ± 7.7 (47) 57.6 ± 7.8 (68) −0.21 (early onset)
6 119 D6S474 0.040 58.1 ± 6.5 (52) 54.5 ± 8.6 (63) 0.17 (late onset)
16 23 D16S748 0.040 57.5 ± 6.8 (58) 54.7 ± 8.8 (57) 0.20 (late onset)
16 87 D16S2624 0.042 57.7 ± 8.5 (50) 54.8 ± 7.3 (65) 0.21 (late onset)
17 80 D17S1290 0.032 55.1 ± 8.8 (50) 56.8 ± 7.2 (65) −0.19 (early onset)
Interaction with duration of diabetes to ESRD
1 143 D1S3723 0.019 10.0 ± 5.5 (40) 8.7 ± 5.5 (55) 0.25 (long duration)
3 31 D1S4545/D3S1259 0.003 10.5 ± 6.1 (41) 8.2 ± 4.7 (54) 0.28 (long duration)
3 182 D3S3053 0.035 11.4 ± 6.1 (34) 8.0 ± 4.7 (61) 0.20 (long duration)
5 8 D5S2849 0.043 10.0 ± 6.1 (43) 8.6 ± 4.8 (52) 0.19 (long duration)
6 155 D6S2436 0.010 10.9 ± 5.8 (43) 7.9 ± 4.8 (52) 0.27 (long duration)
6 178 D6S1277 0.040 9.6 ± 6.1 (46) 8.88 ± 4.9 (49) 0.22 (long duration)
7 7 D7S3056 0.0002 11.0 ± 6.0 (40) 8.0 ± 4.7 (55) 0.39 (long duration)
7 33 D7S1802 0.008 10.4 ± 6.5 (48) 8.0 ± 3.8 (47) 0.22 (long duration)
7 118 D7S1799 0.003 10.7 ± 6.4 (46) 7.8 ± 3.9 (49) 0.27 (long duration)
7 171 D7S3058 0.007 10.6 ± 6.9 (35) 8.4 ± 4.3 (60) 0.27 (long duration)
08 82 D8S1136 0.042 10.5 ± 6.4 (40) 8.3 ± 4.5 (55) 0.22 (long duration)
12 156 D12S2078/D12S1045 0.031 9.7 ± 5.2 (50) 8.65 ± 5.7 (45) 0.17 (long duration)
13 9 D12S787 0.008 10.3 ± 6.3 (39) 8.5 ± 4.8 (56) 0.25 (long duration)
13 41 D13S325 0.005 10.9 ± 6.3 (36) 8.3 ± 4.7 (59) 0.27 (long duration)
14 12 D14S742 0.014 10.8 ± 5.6 (38) 8.2 ± 5.2 (57) 0.24 (long duration)
15 90 D15S652 0.036 10.2 ± 5.6 (37) 8.58 ± 5.37 (58) 0.20 (long duration)
16 23 D16S748 0.00013 11.2 ± 6.1 (48) 7.2 ± 3.9 (47) 0.34 (long duration)
18 75 D18S851 0.008 10.6 ± 5.4 (46) 7.91 ± 5.3 (49) 0.26 (long duration)
20 90 D20S451 0.006 10.7 ± 5.4 (34) 8.42 ± 5.4 (61) 0.30 (long duration)
Interaction with age at diagnosis of diabetes
1 91 D1S1665 0.004 37.4 ± 8.1 (66) 41.2 ± 8.3 (81) −0.23 (early onset)
2 159 D2S1399/D2S1353 0.023 40.8 ± 8.2 (53) 38.8 ± 8.5 (94) 0.16 (late onset)
3 135 D3S2460 0.036 37.7 ± 8.6 (66) 41.0 ± 8.0 (81) −0.16 (early onset)
4 146 D4S1625 0.005 37.9 ± 7.4 (52) 40.4 ± 8.9 (95) −0.23 (early onset)
6 55 D6S2427 0.024 38.0 ± 7.8 (70) 40.9 ± 8.8 (77) −0.18 (early onset)
9 93 D9S283 0.0001 37.2 ± 7.6 (59) 41.1 ± 8.7 (88) −0.24 (early onset)
10 96 D10S1432 0.041 38.0 ± 8.7 (64) 40.7 ± 8.1 (83) −0.17 (early onset)
10 171 D10S212 0.003 41.3 ± 8.5 (76) 37.6 ± 8.9 (71) 0.24 (late onset)
12 22 GATA49D12/D12S391 0.009 41.4 ± 9.1 (69) 37.8 ± 7.4 (78) 0.19 (late onset)
13 21 D13S217/D13S1493 0.006 38.0 ± 7.8 (56) 40.5 ± 8.7 (91) −0.19 (early onset)
13 76 D13S793 0.031 37.7 ± 8.6 (67) 41.1 ± 8.1 (80) −0.19 (early onset)
14 44 D14S306 0.025 37.9 ± 7.8 (47) 40.3 ± 8.7 (100) −0.17 (early onset)
17 62 D17S1299 0.020 38.2 ± 7.5 (59) 40.4 ± 9.0 (88) −0.18 (early onset)
18 75 D18S851 0.005 36.9 ± 7.2 (67) 41.7 ± 8.8 (80) −0.20 (early onset)
Nominally significant (P < 0.05) results are shown. Interaction P values ≤ 0.005 are shown in bold type.
is noteworthy that this locus, interacting with longer du-
ration of diabetes, was also detected in the ESRD age at
onset interaction analysis with later age at ESRD diagno-
sis. Other interactions with P < 0.01 are on chromosome
3p (31 cM), 7p (at 7 and 33 cM), 7q (171 cM), 13 (at 9
and 41 cM), 18q (75 cM), and 20q (90 cM). There is also
evidence of a 3q locus at 182 cM. This locus is distal to
and significantly separated from the 3q (140 cM) locus,
interacting with age at diagnosis of ESRD. Finally, eval-
uation of interaction with age at diagnosis of diabetes
resulted in 14 loci with significant interactions. The most
significant interaction with age at diabetes diagnosis was
detected on 9q near D9S283 (91 cM, P = 0.0001), in a
subgroup with age at diagnosis 3.9 years earlier as in-
dicated by a Pearson’s correlation coefficient of −0.24.
Additional stronger interactions are detected on chro-
mosome 1p at 91 cM (seen also in ESRD age at diag-
nosis analysis), chromosome 10 at 171 cM (older age at
diagnosis), and chromosome 18q at 75 cM (younger age
at diagnosis; also seen in duration of diabetes to ESRD
analysis).
Ordered subsets analysis with phenotypic traits
OSA is another analytical approach that can be used to
evaluate linkage under assumptions that linkage can be
more readily detected in subgroups of families within a
population, differentiated by specific phenotypic traits.
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Table 4. Ordered subsets analysis (OSA) across the genome of age at diagnosis ESRD, duration of type 2 diabetes to ESRD, or age at diagnosis
of diabetes of African American ESRD families
Mean ± SD
Linked Position Nearest Entire sample Maximized Optimal Remaining Empirical P value %
Chromosome subset cM marker LOD LOD subset families for change Peds
Subsetting by age at diagnosis of ESRD
3 Early onset 135 D3S2460 1.27 4.55 46.8 ± 4.6 59.7 ± 5.6 0.004 29
17 Early onset 67.5 D17S2180 0.04 1.76 41.5 ± 3.3 57.7 ± 6.4 0.047 10
Subsetting by duration of diabetes to ESRD
7 Longer duration 33 D7S1802 1.47 3.59 14.3 ± 4.6 6.0 ± 2.9 0.011 37
12 Longer duration 158.5 D12S1045 0.78 2.94 14.5 ± 4.6 6.1 ± 2.9 0.025 36
13 Longer duration 17 D13S217 0.06 1.92 18.1 ± 4.2 7.3 ± 3.4 0.024 17
16 Longer duration 23 D16S748 0.04 2.85 17.1 ± 4.3 7.0 ± 3.3 0.013 21
Subsetting by age at diagnosis of diabetes
3 Early onset 135 D3S2460 0.29 2.52 28.8 ± 2.8 43.9 ± 7.5 0.015 18
10 Late onset 161.5 D10S217 0.41 2.65 54.4 ± 4.50 38.3 ± 6.8 0.035 19
12 Late onset 39 D12S373 0.70 2.86 46.5 ± 6.5 32.7 ± 5.2 0.035 64
18 Early onset 100.5 D18S1364 1.64 3.72 35.7 ± 5.4 50.7 ± 5.2 0.009 64
19 Late onset 21 D19S1034 0.60 3.13 51.3 ± 5.0 36.3 ± 5.8 0.020 34
20 Late onset 39 D20S470 0.027 2.50 56.2 ± 4.5v 39.2 ± 7.3 0.009 13
21 Late onset 57 D21S1446 0.45 2.59 52.2 ± 4.7 36.9 ± 6.1 0.009 29
Maximized LOD scores ≥3.0 are shown in bold type.
This approach was used to search for differential evi-
dence for linkage depending on the age at diagnosis for
ESRD, duration of diabetes before ESRD onset, and age
at diagnosis of diabetes: the same traits used in the NPL
regression interaction analysis. Regions displaying a sig-
nificant change in chromosome-specific P value (P <
0.05) are shown in Table 4. One region on the long arm
of chromosome 3 near D3S2460 at 135 cM exhibited an
OSA maximum LOD score of 4.55 in an optimum sub-
set analysis on the 48 pedigrees (29%), with the earliest
age at diagnosis compared to a LOD score overall of
1.27 (chromosome-wide P value, P = 0.004). The op-
timum linked family set had an age at onset of ESRD
almost 13 years earlier than the remaining families. This
chromosome 3 locus was also significant when subsetting
on age at diabetes diagnosis. Figure 1A shows the LOD
score graph for chromosome 3 with the NPL single locus
regression and OSA results. Note that the OSA incorpo-
rates calculation of an empirical chromosome-specific P
value (in this case P = 0.004) to evaluate whether these re-
sults could be randomly expected. Three other loci, one
subsetting on longer duration of diabetes to ESRD on
7p (optimal subset LOD = 3.59, 37% of pedigrees), and
two loci on 18q (optimal subset LOD = 3.72; 64% of
pedigrees) and 19q (optimal subset LOD = 3.13; 34%
of pedigrees) subsetting on age at diabetes diagnosis and
subsetting on earlier and later onset of diabetes, respec-
tively, also had optimal LOD scores greater than 3. The
LOD score graphs for the chromosome 7 and 18 OSA
results are shown in Figure 1B and C, respectively, which
show NPL multilocus regression results in addition to
the single locus NPL regression and OSA. (The multilo-
cus NPL regression did not reach statistical significance
for chromosome 3). Eight additional chromosomal re-
gions provided chromosome-wide statistically significant
(P < 0.05) increases in the LOD score based upon sub-
set analysis for early diagnosis of ESRD, longer duration
of diabetes to ESRD, and either earlier or later diagnosis
of diabetes (Table 4).
For the chromosome 3, 7, and 18 OSA results we have
assessed whether the characteristics of the families in the
optimal subset varied significantly from characteristics in
the rest of the families in the study. These results are
summarized in Table 5, which shows the mean and stan-
dard deviation and medians for linked and unlinked pedi-
grees, and reports the P value from the GEE1 analysis
(see Methods). The chromosome 3 optimal subset was
based on earlier age of diagnosis of ESRD, which is, as
expected, significantly different between the two sets of
families. Other traits are also significantly different: du-
ration of diabetes to ESRD, age at recruitment, and age
at diagnosis of diabetes. Each of these traits is correlated
with age of ESRD diagnosis, so this is not surprising. The
chromosome 7 optimal subset was based on longer dura-
tion of diabetes to ESRD, which is significantly different
between the two sets of families. Other traits are also sig-
nificantly different: age at diagnosis of diabetes strongly,
and age and BMI more weakly. Age at diagnosis of dia-
betes and age are, again, correlated with duration of dia-
betes. The lower BMI in the optimal subset may reflect the
long-term effects of diabetes on the health, and, as such,
the BMI of the longer duration of diabetes individuals.
Finally, the chromosome 18 optimal subset was based on
earlier age of diagnosis of T2DM, which is significantly
different between the two sets of families. Other traits are
also significantly different: duration of diabetes to ESRD,
age at recruitment, and age at diagnosis of ESRD. Again,
each of these age-related traits is correlated, at least in
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Fig. 1. Logarithm of odds (LOD) score results with (A) chromosome
3, earlier mean age at end-stage renal disease (ESRD) pedigrees, (B)
chromosome 7, longer duration of diabetes to ESRD, and (C) chro-
mosome 18, earlier age of diagnosis of diabetes. Marker locations are
shown across the top, and map position in cM is shown along the bot-
tom. Solid line = single locus nonparametric linkage (NPL) regression;
small dashed line = OSA subset analysis; long dashed line = multilo-
cus NPL regression. The NPL multilocus analysis was not included for
chromosome 3 because it did not reach statistical significance. Physical
map locations of the peak LOD scores from UCSC Genome Browser
(http://genome.ucsc.edu/) are: chromosome 3, 118623238 bp; chromo-
some 7, 20349565 bp; chromosome 18, 61649324 bp.
part, with the analysis trait (in this case, age of diabetes
diagnosis). The means and SDs reported in Tables 4 and
5 differ in the case of chromosomes 3 and 18 modestly,
and in the case of chromosome 7 to a greater degree, due
to the family means being used in the OSA analysis and
individual means being compared in Table 5.
DISCUSSION
To our knowledge this investigation represents the first
large-scale effort to map chromosomal locations of genes
specifically contributing to T2DM-associated ESRD and
nephropathy in the African American population. There
are only two other complete reports of genome scans for
diabetic nephropathy. Imperatore et al [22] carried out a
genome scan for microvascular disease in 98 Pima Indian
diabetes-affected sibling pairs and identified evidence for
linkage to nephropathy on chromosome 7q, and sugges-
tive evidence for linkage on 3q, 9q, and 20p. Vardarli et al
[23] carried out a genome scan in 18 large Turkish families
with T2DM and diabetic nephropathy and found strong
evidence for linkage (LOD = 6.1) on 18q22.3–23. Evalu-
ation of these loci in the Pima Indian dataset also showed
evidence of confirmation (P = 0.013–0.006), although this
region was not linked in the original Pima genome screen.
In one other study, Moczulski et al [24] carried out a fo-
cused analysis of several genomic regions and identified
evidence for linkage at nephropathy in type 1 diabetes
families on the long arm of chromosome 3 in the region
of the angiotensin II type 1 receptor (ATR1).
In carrying out this study we proceeded from the as-
sumptions that DN is a genetically complex disease that
has both genetic and environmental and lifestyle compo-
nents. Consequently, a realistic search for ESRD genes
requires consideration of both multigenic and phenotypic
influences. This study incorporates relatively novel ap-
proaches to evaluate these types of interactions (e.g.,
nonparametric linkage regression multilocus modeling
and ordered subsets analysis). We used OSA based on
phenotypes such as age at onset of ESRD and diabetes,
and duration of diabetes before ESRD onset, in an effort
to define more homogeneous subgroups of families that
could potentially reveal evidence of linkage.
Only limited evidence of linkage was evident at the
first stage at analysis (Table 2) with 4 LOD scores ≥1.0,
but less than 2, with the highest LOD score in 7p. In the
multilocus analysis, incorporating an evaluation of het-
erogeneity, 5 chromosomal regions showed evidence of
significant interaction in the multilocus models, with the
strongest evidence (LOD = 1.63) on 16p. When analytical
approaches that incorporate phenotypic trait data were
applied, as summarized in Tables 3 and 4, evidence for
multiple chromosomal loci contributing to ESRD sus-
ceptibility was revealed. In fact, with the NPL regres-
sion analysis evaluating interactions with age at ESRD
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Table 5. Characteristics of families in the ordered subset analyses
Unlinked # of pedigrees = 82 Linked # of pedigree = 33
Trait Mean (SD) Median (N) Mean (SD) Median (N) P value
Chromosome 3 subset: Subsetting by age at diagnosis of ESRD
Diabetes to ESRD 19.38 (9.32) 19 (183) 15.34 (5.73) 15 (59) 0.002
Age 60.42 (10.03) 61 (331) 51.89 (6.71) 53 (72) <0.0001
ESRD age of onset 58.83 (8.5) 59 (210) 46.91 (6.06) 48 (70) <0.0001
T2DM age of diagnosis 41.34 (11.6) 41 (324) 34.38 (8.08) 34 (72) <0.0001
BMI 30.98 (7.33) 29.88 (328) 32.01 (7.29) 31.57 (68) 0.26
Unlinked # of pedigrees = 82 Linked # of pedigree = 37
Mean (SD) Median (N) Mean (SD) Median (N) P value
Chromosome 7 subset: Subsetting by duration of diabetes to ESRD
Diabetes to ESRD 16.16 (7.32) 15 (164) 23.09 (8.95) 22 (78) <0.0001
Age 58.29 (10.58) 58 (329) 61.59 (6.72) 62 (74) 0.018
ESRD age of onset 55.14 (10.04) 54 (201) 57.65 (7.66) 58 (79) 0.069
T2DM age of diagnosis 41.4 (11.35) 41 (315) 34.91 (9.87) 33 (81) <0.0001
BMI 31.70 (7.44) 30.96 (322) 28.81 (6.31) 27.68 (74) 0.022
Unlinked # of pedigrees = 82 Linked # of pedigree = 141
Mean (SD) Median (N) Mean (SD) Median (N) P value
Chromosome 18 subset: Subsetting by age at diagnosis of diabetes
Diabetes to ESRD 15.15 (7.29) 13 (62) 19.51 (8.95) 19 (180) 0.0003
Age 63.98 (8.76) 64 (137) 56.28 (9.69) 56 (266) <0.0001
ESRD age of onset 61.21 (8.3) 61 (91) 53.27 (8.94) 53 (189) <0.0001
T2DM age of diagnosis 49.5 (9.17) 50 (118) 36.08 (9.72) 35 (278) <0.0001
BMI 30.57 (7.45) 29.19 (135) 31.46 (7.25) 30.50 (261) 0.45
HBA1C 8.69 (2.81) 8.1 (47) 8.83 (2.35) 8.25 (72) 0.99
SD, standard deviation; N, number of subjects.
diagnosis, duration of diabetes before ESRD, and age at
diabetes diagnosis, a large number of loci: 9, 19, and 14,
respectively, showed significant evidence for linkage.
Using the OSA approach (Table 4) to subset families
ranked based on these phenotypic traits identified subsets
which, in some cases, showed dramatic increases in LOD
scores compared with the entire family set. The most dra-
matic example is the chromosome 3q locus where subset-
ting based on age at ESRD diagnosis revealed a subset of
families with earlier onset of ESRD that had a combined
LOD score of 4.55 compared to a LOD score of 1.27 for
the entire sample. One challenge of using novel analyti-
cal approaches is to assess the significance of the resulting
LOD score (in this case of OSA). For the OSA analysis an
empiric chromosome specific P value has been calculated
for chromosome 3 (P = 0.004), which suggests that the
LOD score does indeed represent significant evidence for
linkage.
Faced with a large number of potentially linked loci,
it is challenging to evaluate significance and to prioritize
which regions are most likely to contain ESRD genes.
Overall, there is no overwhelming evidence for linkage
in the entire sample but each of the major peaks (chro-
mosomes 3, 7, and 18) in the OSA analyses have LOD
scores over 3.5 and, in the case of the chromosome 3 anal-
ysis subsetting on age of ESRD diagnosis, a LOD over
4.5. These are, however, maximized LODs under optimal
conditions, and conventionally used criteria for evidence
of linkage (e.g., Lander and Kruglyak, [25]) do not di-
rectly apply. As in any genome scan, one must be mindful
that some of these linkage results could represent chance
events.
We have weighed their significance using multiple crite-
ria: magnitude of LOD scores, consistent evidence of link-
age in multiple analysis approaches, and evidence from
other genome scans and other genetics studies. Several of
the loci detected here show consistent evidence of linkage
using each of these criteria. As outlined above, the high-
est LOD score was observed in the OSA on chromosome
3q at 135 cM (Table 4) when subsetting on age at ESRD
diagnosis. Consistent with this observation, NPL regres-
sion analysis detected evidence for linkage to this same
locus in the interaction analysis with age at ESRD onset
(P = 0.016) and age at diabetes diagnosis (P = 0.036).
Each of these linkage results, as with the ordered sub-
set analysis, is with earlier age at diagnosis. Evidence for
linkage to 3q was also observed by Moczulski et al [24] in
type 1 diabetes-associated nephropathy, and by Impera-
tore et al [22] in the Pima Indians, although linkage peak
in the Pimas appears to be more distal (approximately
180 cM).
In addition, there is evidence of linkage on 7p at ap-
proximately 29 cM in the NPL single locus and multi-
locus analysis. This locus is also detected in the NPL
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interaction analysis with duration of diabetes before
ESRD (P = 0.008 at 33 cM), and the OSA, where a sub-
set of 37% of the families with longer duration between
diabetes diagnosis and ESRD onset had a LOD score
of 3.59. Another interesting locus is on 18q at approxi-
mately 100 cM. This locus has LOD scores of 1.0 and 1.34
in the single locus and multilocus NPL regression analy-
sis, respectively, and a max. LOD score of 3.72 in families
subsetted based on age at diabetes diagnosis in the OSA.
This 18q location is the same area as the linkage reported
by Vardarli et al [23]. Finally, in an earlier report from our
laboratory we detected evidence for linkage with markers
in 10q [26, 27] in a collection of families that contained
both diabetic and non-diabetic ESRD families. In this
study with a larger number of families (including the pre-
viously genotyped DN families described in Freedman et
al [10]) and restricted to diabetes-associated nephropa-
thy, evidence for linkage was reduced, though specific
NPL regression analysis (P = 0.003) and OSA (optimal
LOD = 2.65) still suggest evidence of linkage on chro-
mosome 10q.
In another approach, we have compared the demo-
graphic characteristics of individuals in families that con-
tributed to the evidence for linkage on chromosome 3, 7,
and 18 using OSA with subjects from families that were
not part of the optimal subset (Table 5). There are no un-
expected differences between the subjects. Most of the
significant differences are correlated with different mea-
sures of age (simple age, diabetes diagnosis, ESRD di-
agnosis, duration of diabetes to ESRD), all of which are
correlated. It is interesting to note however, that there is
only modest overlap in the families contributing to the
OSA optimal subsets. For example the overlap between
the chromosomes 3 and 7 optimal subsets is 7 of 29 and 37
families respectively (data not shown). This suggests that
these linkages may indeed represent different DN loci.
This study evaluated families with sibling pairs that
were concordant for both diabetes and renal disease. As
such, the question arises of whether the evidence of link-
age that we observe is to ESRD or diabetes. The families
that made up this study are a subset of a significantly
larger collection of African American families with mul-
tiple cases of type 2 diabetes. The African American dia-
betes families have also been the subject of a genome scan
and subsequent analysis. There is little or no evidence for
linkage to the 3q or 18q loci in the diabetes genome scan,
so these seem likely to be true ESRD loci. In contrast,
a major peak in the diabetes scan was observed on 7p
and is associated with early age at diabetes diagnosis and
lower BMI. In the DN scan, this 7p peak is not signifi-
cantly associated with early age at diabetes diagnosis, but
is associated with duration of diabetes before diagnosis
of ESRD. We have also evaluated this DN peak for in-
teraction with BMI, and similar to the T2DM peak, there
is evidence of interaction with lower BMI (P = 0.035).
Therefore, we cannot exclude the possibility that this rep-
resents a T2DM gene. It is possible that a genome scan
currently underway in our group in nondiabetic families
with ESRD will help clarify which phenotype is being
mapped on chromosome 7p.
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